Start in 1976 Pyridam established with small factory. In 1985, Pyridam established its Pharmaceutical Division, which develop quickly. Pyridam was awarded the title “Partner with Good Performance” in 1994 by the Ministry of Agriculture and Accelerated improvement enabled Pyridam to build a brand new production plant on 35,000 sqm land in Cianjur, West Java, with state of the art design, machinery, and environmental management. The plant started its operation in April 2001.
OUR MOTTO
Live a healthier life with Pyridam Farma
Vision
To become one of the leading healthcare solution company in Indonesia that continues to innovate and produces variety of high quality products
Mission
1. Continue to do research and development to produce the best products
2. Establish collaboration with eminent business partner in their respective field
3. Develop skillful human resources that adaptive to changes
Company values (The Pylars):
Brief History
1985
PT Pyridam diversified its business by producing and marketing human medicines at the initial stage of its business expansion.
At the same time, the Company was also honored by several overseas principals with marketing rights of their health equipment products in territory of Indonesia, particularly in the laboratory apparatus/equipment sector.
2001
PT Pyridam started operating its new factory located in Pacet, Cianjur.
In the same year, PT Pyridam completed an Initial Public Offering (IPO) of 120,000,000 ordinary shares, and since then, it was registered at the Jakarta Stock Exchange, which later changed its name to Indonesia Stock Exchange. Following the completion of IPO, the Company name was changed to PT Pyridam Farma, Tbk.
2005
PT Pyridam Farma, Tbk. obtained ISO certificate 9001:2000 through SGS for all sectors of its businesses.
The organization and all business activities of the Company were therefore, in conformity with the international standard.
2011
In September 2011, the Company had successfully obtained ISO 9001: 2008, upgraded from the previous version ISO 9001: 2000.
This should serve to demonstrate the Company’s determination in maintaining and improving its management system by adopting the newer updated version to meet the international standard.
2013
PT. Pyridam Farma Tbk. succeeded to obtain cGMP certificate after having completed the total renovation of its production facility that had been carried-out since November 2012.
PT Pyridam Farma Tbk. completed its total factory renovation works by mid of 2014 as also adding purified water sysytem utilizing reverse osmosis technology and centralized air conditioning system replacing the old one – to meet the requirements of the current GMP (cGMP). Thereupon, it succeeded to obtain the cGMP certification by the National Food and Drugs Administration (BPOM). Along with the total factory renovation, PT Pyridam Farma Tbk. also carried out its production capacity expansion.
2017
he Company has also obtained Current Good Manufacturing Practices (Traditional Medicine) (CPOTB) for effervescent powder and tablet which is valid until 14 August 2022.
2018
In 2018, the Company succeeded in obtaining a “halal certificate” issued by the relevant authorities, that is, LPPOM – MUI on 12 December 2018 valid until December 11, 2020.
In 2018 the Company succeeded to get cGMP extension for all product processes and dosage forms with a validity period up to September 25, 2023, while cGMP for herbal products is still valid until April 13, 2020.
2019
In 2019, the Company obtained an ISO/IEC 17025: 2017 Certificate.
In 2019, the Company obtained an ISO/IEC 17025: 2017 Certificate as a Testing Laboratory issued by the National Accreditation Committee (KAN) with a validity period until July 22, 2024.
2020
On July 20, 2020, there was a transfer of the Company’s shares from PT Pyridam Internasional to Rejuve Global Investment Pte Ltd amounting to 254,736,579 shares or around 47.61% of the Company’s total shares.
The change of ownership has made Rejuve Global Investment Pte Ltd. as a controller of the Company. The takeover of the Company was announced in Harian Neraca on July 21, 2020 by Rejuve Global Investment Pte Ltd.
Then the company moved its head office to:
Sinarmas MSIG Tower 12th Floor, Jl. Jend. Sudirman No.Kav. 21, RT.10/RW.1, Kuningan, Karet, Kecamatan Setiabudi, Kota Jakarta Selatan, Jakarta 12920 – Indonesia.
In addition, in 2020 the Company started its investment in PYFA Health Singapore Pte Ltd, in amount of 990 shares or around 99.00 % of shares in such company, whereby its business activities are engaged in research and experimental development on biotechnology, life, and medical science.
In 2020, the Company obtained an ISO 9001 : 2015 certificate for Sales, Marketing, and Manufacturing of Pharmaceuticals, Natural Medicines, Household product, and Health Suplement, and also Sales and Marketing of Medical Devices issued by SGS United Kingdom Ltd with a validity period until September 9, 2023.
2021
Pyridam Farma Rapid Growth
1. Bonds
On 14 January 2021, the Company issued Pyridam Farma Bonds I Year 2020 of IDR 300 Billion; which such bonds were listed at the Indonesia Stock Exchange on 15 January 2021.
2. Opening Representative Office in South Korea
On 22 February 2021, to support its business activities, the Company has opened a representative office in South Korea with the following address: 1252, 369, Gangnam-daero. Seocho-gu, Seoul, Republic of Korea .
3. Halal Certificate
On 19 March 2021 the Company obtained a Halal Certificate for Supplement products namely Ferospat Effervescent, Osteor, Osteor Plus, Osteor Plus Effervescent Tablet and Sangobion Fizz.
4. ISO Certificate
On 23 April 2021 the Company obtained ISO 9001:2015 Certificate from SGS for Sales, Marketing, Natural Medicines, Household Product, and Health Supplement, Sales and Marketing of Medical Devices.
5. Establishment of 4 (Four) Subsidiaries
On 22 and 23 March 2021, 4 (four) subsidiaries have been established as follow:
a. PT PYFA MEDIKA INDONESIA, which is engaged in, among others, retail trade of pharmaceutical goods in pharmacies; laboratory, pharmaceutical and health equipment; laboratory testing services; and activities to support health services.
b. PT MEGA INTER DISTRINDO, which is engaged in, among others, large trade in pharmaceutical; traditional medicine; cosmetics; as well as laboratory, pharmaceutical and medical equipment.
c. PT PYFA INVESTAMA MEDIKA, which is engaged in, among others, large trade with fees or based on contracts; holding company activities; accounting bookkeeping and auditing activities; other management consulting activities; business consulting and business brokerage activities; and the activities of joint office adiministration service providers.
d. PT PYFA SEHAT INDONESIA, which is engaged in, among others, (i) retail trade of pharmaceutical goods in pharmacies and non-pharmacies; traditional medicine; cosmetics; laboratory; pharmaceutical and health equipment; (ii) retail trade through the media; (iii) pakaging activities; and (iv) web portals and/or digital platforms for commercial purposes.
6. The Completion of the Subscription of New Shares in the Fullerton Health Indonesia Group by PT Pyfa Investama Medika
One of the Company’s subsidiaries, PT Pyfa Investama Medika (PIM), completed the transaction of subscription of new shares which results in PIM having minority shareholding of 10% of issued and paid up capital (outside treasury shares) in PT E-Tirta Medical Centre, PT Fullerton Health Indonesia, PT Global Assistance and Healthcare, and PT Global Asistensi Medika (parts of Fullerton Health Indonesia Group) on 4 June 2021.
7. Awards
Throughout 2021, the Company has received numerous awards, among others: (i) Top 5 Performing Listed Companies: Top 5 Rising Company in the Pandemic Era award from Investor Magazine, (ii) Indonesia Best Business Transformation award from SWA Magazine, and (iii) Top 50 Best of The Best Public Listed Companies from Forbes Indonesia.
8. The Completion of the Shares Acquisition in PT Holi Pharma by PT Pyridam Farma Tbk
The Company has acquired the shares of PT Holi Pharma (HP) on 28 December 2021. HP is a company engaged in the field of, among others, industry of human related pharmaceutical product, including the business of manufacturing and processing medicines and health supplements.